依达拉奉联合硫酸氢氯吡格雷治疗脑梗死的临床效果
|
摘要
目的探讨依达拉奉联合硫酸氢氯吡格雷治疗脑梗死的临床效果。方法选取2017年1～12月我院神经内科收治的38例脑梗死患者作为研究对象,根据患者入院病历号采用随机数字表法将其分为观察组(20例)和对照组(18例)。对照组患者采用常规治疗,即应用阿司匹林、降脂药、营养神经药;观察组患者采用依达拉奉联合硫酸氢氯吡格雷进行治疗。7 d为1个疗程,治疗2个疗程。比较两组患者的临床治疗总有效率、治疗前后神经功能缺损评分(NIHSS)、生活能力评分(BI)、超氧化物歧化酶(SOD)、丙二醛(MAD)水平。结果观察组患者的临床治疗总有效率为90.00%,高于对照组的61.11%,差异有统计学意义(P<0.05)。两组患者治疗前的NIHSS、BI评分比较,差异无统计学意义(P>0.05);两组患者治疗后的NIHSS评分均低于治疗前,BI评分均高于治疗前,差异有统计学意义(P<0.05);观察组患者治疗后的NIHSS评分低于对照组,BI评分高于对照组,差异有统计学意义(P<0.05)。两组患者治疗前的SOD、MAD水平比较,差异无统计学意义(P>0.05);两组患者治疗后的SOD水平均高于治疗前,MAD水平均低于治疗前,差异有统计学意义(P<0.05);观察组患者治疗后的SOD水平高于对照组,MAD水平低于对照组,差异有统计学意义(P<0.05)。结论依达拉奉联合硫酸氢氯吡格雷治疗脑梗死患者的效果更好,能够有效恢复患者的神经功能,调节SOD、MAD水平,增强机体抗氧化能力,提高患者的生活能力。
Objective To explore the clinical effect of Edaravone combined with Clopidogrel Hydrogen Sulfate in the treatment of cerebral infarction.Methods A total of 38 patients with cerebral infarction admitted to neurology department of our hospital from January to December 2017 were selected as research objects and according to their admission medical record number,they were divided into observation group(20 cases) and control group(18 cases) by random number table method.Patients in the control group received conventional treatment,like Aspirin,lipid-lowering drugs,and nutrient neuropharmaceuticals and patients in the observation group were treated with Edaravone combined with Clopidogrel Hydrogen Sulfate.One course of treatment was 7 days,with a total of 2 courses of treatment.The total effective rate of clinical treatment,neurological deficit score(NIHSS),viability score(BI),superoxide dismutase(SOD),and malondialdehyde(MAD) levels before and after treatment were compared between the two groups.Results The total effective rate of clinical treatment in the observation group was 90.00%,which was higher than that in the control group(61.11%),and the difference was statistically significant(P<0.05).There were no significant differences in NIHSS and BI scores between the two groups before treatment(P>0.05).The NIHSS scores of the two groups after treatment were lower than those before treatment,the BI scores were higher than those before treatment,and the differences were statistically significant(P<0.05).The NIHSS score of the observation group after treatment was lower than that of the control group,the BI score was higher than that of the control group,and the differences were statistically significant(P<0.05).There were no significant differences in the levels of SOD and MAD between the two groups before treatment(P>0.05).The SOD levels after treatment in the two groups were higher than those before treatment,the MAD levels were lower than those before treatment,and the differences were statistically significant(P<0.05).The level of SOD in the observation group was higher than that in the control group,the MAD level was lower than that in the control group,and the differences were statistically significant(P<0.05).Conclusion Edaravone combined with Clopidogrel Hydrogen Sulfate has better therapeutic effect on patients with cerebral infarction.It can effectively restore the patients′ nerve function,and regulate SOD and MAD levels to enhance the body′s antioxidant capacity and improve the patients′ life ability.
Objective To explore the clinical effect of Edaravone combined with Clopidogrel Hydrogen Sulfate in the treatment of cerebral infarction.Methods A total of 38 patients with cerebral infarction admitted to neurology department of our hospital from January to December 2017 were selected as research objects and according to their admission medical record number,they were divided into observation group(20 cases) and control group(18 cases) by random number table method.Patients in the control group received conventional treatment,like Aspirin,lipid-lowering drugs,and nutrient neuropharmaceuticals and patients in the observation group were treated with Edaravone combined with Clopidogrel Hydrogen Sulfate.One course of treatment was 7 days,with a total of 2 courses of treatment.The total effective rate of clinical treatment,neurological deficit score(NIHSS),viability score(BI),superoxide dismutase(SOD),and malondialdehyde(MAD) levels before and after treatment were compared between the two groups.Results The total effective rate of clinical treatment in the observation group was 90.00%,which was higher than that in the control group(61.11%),and the difference was statistically significant(P<0.05).There were no significant differences in NIHSS and BI scores between the two groups before treatment(P>0.05).The NIHSS scores of the two groups after treatment were lower than those before treatment,the BI scores were higher than those before treatment,and the differences were statistically significant(P<0.05).The NIHSS score of the observation group after treatment was lower than that of the control group,the BI score was higher than that of the control group,and the differences were statistically significant(P<0.05).There were no significant differences in the levels of SOD and MAD between the two groups before treatment(P>0.05).The SOD levels after treatment in the two groups were higher than those before treatment,the MAD levels were lower than those before treatment,and the differences were statistically significant(P<0.05).The level of SOD in the observation group was higher than that in the control group,the MAD level was lower than that in the control group,and the differences were statistically significant(P<0.05).Conclusion Edaravone combined with Clopidogrel Hydrogen Sulfate has better therapeutic effect on patients with cerebral infarction.It can effectively restore the patients′ nerve function,and regulate SOD and MAD levels to enhance the body′s antioxidant capacity and improve the patients′ life ability.
引文
[1]高长玉,吴成翰,赵建国,等.中国脑梗死中西医结合诊治指南(2017)[J].中国中西医结合杂志,2018,38(2):136-144.
[2]中华医学会神经病学分会.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志,2015,48(4):246-257.
[3]罗祖明,刘凌,商惠芳.急性缺血性脑卒中病人三种神经功能缺损程度评分与巴氏指数的相关性[J].中华老年心脑血管病杂志,2001,3(4):241-243.
[4]黄伟,孟庆伟.不同亚型分水岭脑梗死的发病机制及临床特点分析[J].中西医结合心脑血管病杂志,2016,14(2):191-192.
[5]杜真真,张灿飞,汤媛媛,等.大动脉粥样硬化性脑梗死不同发病机制的危险因素分析[J].中华老年心脑血管病杂志,2016,18(4):394-397.
[6]李柏胜.血管介入与保守方案治疗急性脑梗死的疗效及对纤溶活性水平的影响[J].中国实用神经疾病杂志,2016,19(10):112-113.
[7]任杰.大面积脑梗塞的临床特点与治疗[J].临床研究,2016,24(11):34-35.
[8]张楠楠,陈会生.依达拉奉对脑梗死大鼠神经保护作用最佳治疗时间窗的探讨[J].解放军医药杂志,2016,28(3):18-21.
[9]邓增.早期高压氧治疗对急性脑出血患者脑水肿和氧化应激产物水平的影响[J].检验医学与临床,2016,13(24):3528-3530.
[10]黄革丽.阿司匹林联合硫酸氢氯吡格雷口服治疗脑梗死的有效性和安全性研究[J].中国实用医药,2017,12(15):110-111.
[11]王立羽,白丽虹,王爽.硫酸氢氯吡格雷联合阿司匹林肠溶片治疗脑梗死的疗效及对血清高敏C反应蛋白、血脂、颈总动脉内膜中层厚度的影响[J].广西医学,2017,39(4):481-483.
[12]许晓敬,贾阳娟,韩凝,等.NIHSS评分对急性脑梗死颅内大动脉闭塞的预测价值[J].脑与神经疾病杂志,2016,24(9):544-548.
[13]夏慧,胡婷婷,陆悌明.依达拉奉治疗急性脑梗死的疗效及对炎症因子与NIHSS评分的影响[J].实用临床医药杂志,2017,21(1):150-151.
[14]李继英,赵杨,张臻年,等.通脑活络针刺疗法对急性脑梗死患者BI、NIHSS评分的影响[J].中国中西医结合杂志,2011,31(1):28-32.
[15]梁允强,陈石伙,陈东燃.疏血通注射液治疗脑梗塞的效果及对CSS和BI评分的影响[J].白求恩医学杂志,2016,14(1):55-56.
[2]中华医学会神经病学分会.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志,2015,48(4):246-257.
[3]罗祖明,刘凌,商惠芳.急性缺血性脑卒中病人三种神经功能缺损程度评分与巴氏指数的相关性[J].中华老年心脑血管病杂志,2001,3(4):241-243.
[4]黄伟,孟庆伟.不同亚型分水岭脑梗死的发病机制及临床特点分析[J].中西医结合心脑血管病杂志,2016,14(2):191-192.
[5]杜真真,张灿飞,汤媛媛,等.大动脉粥样硬化性脑梗死不同发病机制的危险因素分析[J].中华老年心脑血管病杂志,2016,18(4):394-397.
[6]李柏胜.血管介入与保守方案治疗急性脑梗死的疗效及对纤溶活性水平的影响[J].中国实用神经疾病杂志,2016,19(10):112-113.
[7]任杰.大面积脑梗塞的临床特点与治疗[J].临床研究,2016,24(11):34-35.
[8]张楠楠,陈会生.依达拉奉对脑梗死大鼠神经保护作用最佳治疗时间窗的探讨[J].解放军医药杂志,2016,28(3):18-21.
[9]邓增.早期高压氧治疗对急性脑出血患者脑水肿和氧化应激产物水平的影响[J].检验医学与临床,2016,13(24):3528-3530.
[10]黄革丽.阿司匹林联合硫酸氢氯吡格雷口服治疗脑梗死的有效性和安全性研究[J].中国实用医药,2017,12(15):110-111.
[11]王立羽,白丽虹,王爽.硫酸氢氯吡格雷联合阿司匹林肠溶片治疗脑梗死的疗效及对血清高敏C反应蛋白、血脂、颈总动脉内膜中层厚度的影响[J].广西医学,2017,39(4):481-483.
[12]许晓敬,贾阳娟,韩凝,等.NIHSS评分对急性脑梗死颅内大动脉闭塞的预测价值[J].脑与神经疾病杂志,2016,24(9):544-548.
[13]夏慧,胡婷婷,陆悌明.依达拉奉治疗急性脑梗死的疗效及对炎症因子与NIHSS评分的影响[J].实用临床医药杂志,2017,21(1):150-151.
[14]李继英,赵杨,张臻年,等.通脑活络针刺疗法对急性脑梗死患者BI、NIHSS评分的影响[J].中国中西医结合杂志,2011,31(1):28-32.
[15]梁允强,陈石伙,陈东燃.疏血通注射液治疗脑梗塞的效果及对CSS和BI评分的影响[J].白求恩医学杂志,2016,14(1):55-56.